» Articles » PMID: 15188364

Chromatin Breakdown During Necrosis by Serum Dnase1 and the Plasminogen System

Overview
Journal Arthritis Rheum
Specialty Rheumatology
Date 2004 Jun 10
PMID 15188364
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Dnase1-deficient mice with the 129 x C57BL/6 genetic background develop symptoms of systemic lupus erythematosus, such as high titers of antinuclear autoantibodies directed against nucleosomes. In this study we analyzed a potential molecular pathomechanism leading to this autoimmunity, by exploring the influence of extracellular Dnase1 present in serum on the breakdown of chromatin in necrotic cells in vitro.

Methods: Human breast adenocarcinoma cells (MCF-7) and other cell lines were subjected to necrosis induced by hydrogen peroxide, streptolysin O, or freeze-thawing. Subsequently, the influence of sera from Dnase1-deficient and wild-type mice as well as the influence of purified enzymes present in the culture medium on the process of necrotic chromatin breakdown was investigated.

Results: Necrotic chromatin breakdown resembled apoptotic DNA laddering and was catalyzed by serum Dnase1 in conjunction with plasmin. During necrosis, Dnase1 and plasminogen penetrated the cell and accumulated in the cytoplasm and nucleus. Plasminogen bound to the cytoskeleton and nuclear structures, was activated to plasmin by either tissue-type or urokinase-type plasminogen activator, and degraded histone H1, thereby facilitating internucleosomal DNA cleavage by Dnase1.

Conclusion: Our results suggest that serum Dnase1 in cooperation with the plasminogen system guarantees a fast and effective breakdown of chromatin during necrosis by the combined cleavage of DNA as well as of DNA binding proteins. The failure of such a clearance mechanism might lead to antinuclear autoimmunity similar to that observed in the Dnase1-deficient mouse.

Citing Articles

Systemic mechanisms of necrotic cell debris clearance.

Schuermans S, Kestens C, Marques P Cell Death Dis. 2024; 15(8):557.

PMID: 39090111 PMC: 11294570. DOI: 10.1038/s41419-024-06947-5.


Development of a Clonal and High-Yield Mammalian Cell Line for the Manufacturing of a Hyperactive Human DNase I with Extended Plasma Half-Life Using PASylation Technology.

Stamm S, Wagner R, Lang D, Skerra A, Gebauer M Pharmaceutics. 2024; 16(7).

PMID: 39065664 PMC: 11280007. DOI: 10.3390/pharmaceutics16070967.


Emerging role of ferroptosis in metabolic dysfunction-associated steatotic liver disease: revisiting hepatic lipid peroxidation.

Peleman C, Francque S, Vanden Berghe T EBioMedicine. 2024; 102:105088.

PMID: 38537604 PMC: 11026979. DOI: 10.1016/j.ebiom.2024.105088.


NETosis: an emerging therapeutic target in renal diseases.

Juha M, Molnar A, Jakus Z, Ledo N Front Immunol. 2023; 14:1253667.

PMID: 37744367 PMC: 10514582. DOI: 10.3389/fimmu.2023.1253667.


Effect of Pressure Conditions in Uterine Decellularization Using Hydrostatic Pressure on Structural Protein Preservation.

Wang D, Charoensombut N, Kawabata K, Kimura T, Kishida A, Ushida T Bioengineering (Basel). 2023; 10(7).

PMID: 37508841 PMC: 10376797. DOI: 10.3390/bioengineering10070814.